Skip to main content

Table 2 Number and rate of cervical abnormalities for completely vaccinated, partially vaccinated and unvaccinated women

From: Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

Outcome

 

No. women-doses

No. abnormalities

Rate*

Hazard ratio

Histological abnormalities

Any high grade

Unvaccinated

15,192

138

6.4

1.0

 

Vaccinated (unadjusted)

   

0.76 (0.61 to 0.95)

 

Vaccinated (adjusted)

27,179

181

4.8

0.72 (0.58 to 0.91)

 

1 dose

2,568

27

9.7

1.47 (0.97 to 2.23)

 

2 doses

3,412

28

6.8

1.02 (0.68 to 1.53)

 

1 or 2 doses

5,980

55

8.0

1.20 (0.88 to 1.65)

 

Complete

21,199

126

4.1

0.61 (0.48 to 0.78)

CIN3/AIS

Unvaccinated

15,192

61

2.8

1.0

 

Vaccinated (unadjusted)

   

0.68 (0.48 to 0.95)

 

Vaccinated (adjusted)

27,179

70

1.9

0.64 (0.45 to 0.90)

 

1 dose

2,568

12

4.3

1.40 (0.75 to 2.61)

 

2 doses

3,412

11

2.7

0.87 (0.46 to 1.67)

 

1 or 2 doses

5,980

23

3.3

1.09 (0.67 to 1.76)

 

Complete

21,199

47

1.5

0.53 (0.36 to 0.77)

CIN2

Unvaccinated

15,192

87

4.0

1.0

 

Vaccinated (unadjusted)

   

0.81 (0.61 to 1.06)

 

Vaccinated (adjusted)

27,179

122

3.2

0.78 (0.59 to 1.03)

 

1 dose

2,568

16

5.7

1.29 (0.76 to 2.20)

 

2 doses

3,412

18

4.4

0.99 (0.59 to 1.64)

 

1 or 2 doses

5,980

34

4.9

1.11 (0.75 to 1.66)

 

Complete

21,199

88

2.9

0.70 (0.52 to 0.94)

CIN1

Unvaccinated

15,192

163

7.5

1.0

 

Vaccinated (unadjusted)

   

0.86 (0.70 to 1.05)

 

Vaccinated (adjusted)

27,179

244

6.5

0.83 (0.68 to 1.02)

 

1 dose

2,568

20

7.2

0.89 (0.56 to 1.41)

 

2 doses

3,412

30

7.3

0.90 (0.61 to 1.33)

 

1 or 2 doses

5,980

50

7.2

0.90 (0.65 to 1.23)

 

Complete

21,199

194

6.3

0.82 (0.66 to 1.01)

Cytological abnormalities

High-grade cytology

Unvaccinated

15,192

325

15.3

1.0

 

Vaccinated (unadjusted)

   

0.77 (0.67 to 0.89)

 

Vaccinated (adjusted)

27,179

442

11.9

0.75 (0.65 to 0.87)

 

1 dose

2,568

44

16.0

0.85 (0.62 to 1.17)

 

2 doses

3,412

67

16.5

0.95 (0.73 to 1.23)

 

1 or 2 doses

5,980

111

16.3

0.91 (0.73 to 1.13)

 

Complete

21199

331

10.9

0.71 (0.61 to 0.83)

Low-grade cytology

Unvaccinated

15,192

2,306

125.8

1.0

 

Vaccinated (unadjusted)

   

0.77 (0.73 to 0.82)

 

Vaccinated (adjusted)

27,179

3,184

95.3

0.76 (0.72 to 0.80)

 

1 dose

2,568

250

101.9

0.67 (0.59 to 0.76)

 

2 doses

3,412

328

89.2

0.64 (0.57 to 0.72)

 

1 or 2 doses

5,980

578

94.3

0.66 (0.60 to 0.72)

 

Complete

21,199

2,606

95.5

0.79 (0.75 to 0.84)

  1. *Rate per 1,000 person-years.
  2. All high grade histology defined as CIN2, CIN3, AIS and mixed CIN3/AIS.
  3. High-grade cytology defined as possible high-grade squamous intraepithelial lesion (HSIL), HSIL, HSIL with possible microinvasion/invasion, squamous cell carcinoma, possible high-grade endocervical glandular lesion, AIS, AIS with possible microinvasion/invasion and adenocarcinoma.
  4. Low-grade cytology defined as possible low-grade squamous intraepithelial lesions (LSIL), LSIL and atypical endocervical cells of uncertain significance.
  5. Unvaccinated refers to women screened who did not receive any dose of HPV vaccine; completely vaccinated refers to women who were clinically completely vaccinated with three doses of HPV vaccine.
  6. Hazard ratios adjusted for remoteness, SES and age at first screening.